Drug intelligence / Profile preview

AAV9-cTnT-Luciferase

Development stage: Preclinical
Lead developer: University of Miami
Modality: Gene Therapies
Administration: Intravenous

Overview

AAV9-cTnT-Luciferase is a recombinant adeno-associated virus serotype 9 (AAV9) vector designed for heart-specific expression of the firefly luciferase reporter gene. It utilizes the cardiac Troponin T (cTnT) promoter to drive expression specifically in cardiomyocytes. In cardiovascular research, it is primarily used as a control vector or a diagnostic tool to monitor gene delivery efficiency and spatial distribution via bioluminescence imaging. In the context of the provided study, it served as a control for AAV9-cTnT-LDLR in a mouse model of heart failure with preserved ejection fraction (HFpEF).

Beyond the preview

Go deeper on AAV9-cTnT-Luciferase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV9-cTnT-Luciferase.

Explore the full profile